Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.

Literature DB >> 26416151

Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.

Ryan J Sullivan¹, Keith T Flaherty¹.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2015 PMID： 26416151 DOI： 10.1038/nrclinonc.2015.170

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

Review 1. Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors: Francesca Maria Bosisio; Joost J van den Oord
Journal: Virchows Arch Date: 2017-01-05 Impact factor: 4.064

Review 2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors: Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2018-02-15 Impact factor: 8.110

3. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.

Authors: L L Bu; G T Yu; L Wu; L Mao; W W Deng; J F Liu; A B Kulkarni; W F Zhang; L Zhang; Z J Sun
Journal: J Dent Res Date: 2017-06-12 Impact factor: 6.116

4. Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.

Authors: Luya Cai; Xuedan Du; Cheng Zhang; Shanshan Yu; Lixiao Liu; Jinduo Zhao; Ye Zhao; Chunhong Zhang; Jinting Wu; Bin Wang; Yingyu Chen; Xiaoping Su; Xiaojian Yan; Wenfeng Li
Journal: Cancer Immunol Immunother Date: 2021-11-03 Impact factor: 6.630

Review 10. Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis.

Authors: Haisam Abid; Maryam Khavandi; Nadir Siddiqui; Panadeekarn Panjawatanan; Anush Patel
Journal: Cureus Date: 2019-10-25

Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.

Review 1. Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Review 2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

3. STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC.

4. Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.

5. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.

6. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.

Review 7. Focus on cutaneous and uveal melanoma specificities.

Review 8. Small-Molecule Targets in Tumor Immunotherapy.

Review 9. Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment.

Review 10. Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis.